 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Avigen, Inc.
 |
Avigen, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Avigen tests hemophilia gene therapy for liver Aug 16 2001 11:06 AM PDT
Avigen tests hemophilia gene therapy for liver Aug 16 2001 11:06 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Avigen uses viruses as a vector of attack. The company is developing ways to use adeno-associated virus, a nonpathogenic human virus, to deliver therapeutic genes to cells to treat hemophilia, Gaucher disease, Parkinson's disease, and beta-thalassemia. Its lead candidate, Coagulin-B, would treat hemophilia B by allowing for both more potent and less frequent injections of the protein missing or deficient from the blood of hemophiliacs. The company has entered into a marketing agreement with Bayer for the product, which continues in clinical trials. Avigen also has licensing agreements with Research Corporation Technologies and BTG International, as well as various research institutions.
COMPETITION |
 |
Amgen Inc. (AMGN)
Chiron Corporation (CHIR)
Vical Incorporated (VICL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (66.7)%
Employees: 82
Revenue per employee: $1,219.51
KEY PEOPLE |
 |
John Monahan
CEO
Thomas J. Paulson
CFO
CONTACT INFO |
 |
1201 Harbor Bay Pkwy., Ste. 1000
Alameda, CA 94502
US
Phone: 510-748-7150
Fax: 510-748-7155
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |